Fundable for Life, Inc. Partners with FMS Franchise to Provide its Clients TV and Digital Print Media Along with Funding Options
December 13, 2023 08:00 ET
|
Fundable for Life, Inc.
Fundable for Life, Inc. provides business owners channels for media exposure and funding options so they can grow their businesses.
Fundable for Life, Inc. Partners with Top Doctor Magazine to Provide its Members TV and Print Media Along with Funding Options
December 11, 2023 13:05 ET
|
Fundable for Life, Inc.
Fundable for Life, Inc. provides business owners channels for media exposure and funding options so they can grow their businesses.
Alopecia Treatment Market to Reach $14.16 Billion, Globally, by 2030 at 5.6% CAGR: Coherent Market Insights
December 07, 2023 03:14 ET
|
CMI
Burlingame, Dec. 07, 2023 (GLOBE NEWSWIRE) -- According to Coherent Market Insights, The global alopecia treatment market was valued at US$ 9.65 Billion in 2023 and is forecast to reach a value of...
Aclaris Therapeutics Announces Patent License Agreement with Sun Pharma for Alopecia
December 05, 2023 16:01 ET
|
Aclaris Therapeutics, Inc.
WAYNE, Pa., Dec. 05, 2023 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drugs for immuno-inflammatory...
Re:Dish Secures Spot on Inc.'s 2023 Best in Business List By Eliminating Nearly 2 Million Single-Use Packaging Items in First Full Year of Operation
December 05, 2023 10:48 ET
|
Re:Dish Co.
Re:Dish Secures Spot on Inc.'s 2023 Best in Business List By Eliminating Nearly 2 Million Single-Use Packaging Items in First Full Year of Operation
Aclaris Therapeutics Announces Top-line Results from 12-Week Phase 2b Trial of Oral Zunsemetinib (ATI-450) for Moderate to Severe Rheumatoid Arthritis and Provides Corporate Update
November 13, 2023 07:00 ET
|
Aclaris Therapeutics, Inc.
— Study Did Not Meet Primary or Secondary Efficacy Endpoints in Rheumatoid Arthritis — — Efficacy Results Do Not Support Further Development of Zunsemetinib — — Company to Host Conference Call and...
Aclaris Therapeutics Reports Third Quarter 2023 Financial Results and Provides a Corporate Update
November 06, 2023 07:00 ET
|
Aclaris Therapeutics, Inc.
- Topline Data from Zunsemetinib Phase 2b Trial in Rheumatoid Arthritis Expected this Month – - Completion of Enrollment in ATI-1777 Phase 2b Trial in Atopic Dermatitis As Previously Announced;...
Access Recognized for Second Consecutive Year in Inc.’s Annual Power Partner Awards
October 25, 2023 09:00 ET
|
Access Information Management Shared Services, LLC
Roundup highlights B2B partners that support startups across all business functions and empower growth for their clients.
Intetics Is Recognized as Inc. 2023 Power Partner Awards Honoree in the AI & Data Category
October 25, 2023 06:01 ET
|
Intetics Inc.
Inc. named Intetics an honoree on the 2023 Power Partner Awards list in the Artificial Intelligence & Data category.
MarginEdge Recognized by Inc.’s Power Partner Awards and Washington Business Journal’s Fastest Growing Companies 2023
October 24, 2023 08:00 ET
|
MarginEdge
ARLINGTON, Va., Oct. 24, 2023 (GLOBE NEWSWIRE) -- MarginEdge, the leading restaurant management and bill payment platform, today announced it has been recognized by the 2023 Inc. Power Partners...